Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and Haemophilus influenzae type B vaccines to children less than 2 years of age

Pediatrics

Volumn 118, Issue 3, 2006, Pages

  Nolan, Terry ^a   Bernstein, Henry ^b   Blatter, Mark M ^c   Bromberg, Kenneth ^d   Guerra, Fernando ^e   Kennedy, William ^f   Pichichero, Michael ^g   Senders, Shelly D ^h   Trofa, Andrew ⁱ   Collard, Alix ^j   Sullivan, Diane C ⁱ   Descamps, Dominique ^j  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c Primary Physicians Research   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e Main Immunization Clinic   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h Dr Shelly Senders and Associates   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j GSK   (Belgium)

more..

Author keywords

Children; Hepatitis A vaccine; Immunogenicity; Safety

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE; DIPHTHERIA TETANUS PERTUSSIS HAEMOPHILUS B CONJUGATE VACCINE; DIPHTHERIA-TETANUS-PERTUSSIS-HAEMOPHILUS B CONJUGATE VACCINE; HAEMOPHILUS VACCINE; INACTIVATED VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEBRILE CONVULSION; FEVER; GASTROENTERITIS; HEPATITIS A; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SKIN INFLAMMATION; VACCINATION; VOMITING; ANTIBODY PRODUCTION; DISEASE TRANSMISSION; FEMALE; IMMUNOLOGY; MALE;

ANTIBODY FORMATION; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; VACCINES, INACTIVATED;

EID: 33749055991     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2755     Document Type: Article

References (21)

1. World Health Organization. Hepatitis A vaccines. Wkly Epidemiol Rec. 2000;75:38-44
2. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005;294:194-201
3. Bonanni P, Colombai R, Franchi G, Lo Nostro A, Comodo N, Tiscione E. Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. Epidemiol Infect. 1998;121:377-380
4. Rajaratnam G, Patel M, Parry JV, Perry KR, Palmer SR. An outbreak of hepatitis A: school toilets as a source of transmission. J Public Health Med. 1992;14:72-77
5. Staes CJ, Schlenker TL, Risk I, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics. 2000; 106(4). Available at: www.pediatrics.org/cgi/content/full/106/4/e54
6. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, 2006. Harmonized childhood and adolescent immunization schedule, 2006. MMWR Morb Mortal Wkly Rep. 2006;54:Q1-Q4
7. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48:1-37
8. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271:1328-1334
9. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994;44:446-451
10. Yeh SH, Ward JI. Strategies for development of combination vaccines. Pediatr Infect Dis J. 2001;20(suppl 11):S5-S9
11. Ausiello CM, Lande R, Urbani, F, et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis. 2000;181:1989-1995
12. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SG. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr. 1998;132:983-988
13. Centers for Disease Control and Prevention. Summary of notifiable diseases: United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;52:1-85
14. Centers for Disease Control and Prevention. Notice to readers: FDA approval of VAQTA® (hepatitis A vaccine, inactivated) for children aged ≥1 year. MMWR Morb Mortal Wkly Rep. 2005;54:1026
15. Centers for Disease Control and Prevention. Notice to readers: FDA approval of Havrix® (hepatitis A vaccine, inactivated) for persons aged 1-18 years. MMWR Morb Mortal Wkly Rep. 2005;54:1235-1236
16. Centers for Disease Control and Prevention. Hepatitis A. In: Atkinson W, Hamborsky J, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Disease. 8th ed, 2nd printing (January 2005). Washington, DC: Public Health Foundation; 2005:177-189
17. HAVRIX [Hepatitis A, Inactivated] prescribing information. Rixensart, Belgium: GlaxoSmithKline Biologicals; 2003
18. VAQTA [Hepatitis A, Inactivated] prescribing information. Whitehouse Station, NJ: Merck & Co, Inc; 2003
19. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294:202-210
20. Meyerhoff AS, Jacobs RJ. Transmission of hepatitis A through household contact. J Viral Hepat. 2001;8:454-458
21. Smith PF, Grabau JC, Werzberger A, et al. The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect. 1997;118:243-252